Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.
News-Medical.Net on MSN
Redefining control and consistency in anaerobic microbiome workflows
Explore how smart automation enables precise, reproducible workflows in anaerobic microbiome research, improving accuracy and ...
According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass USD 15.62 billion by 2030, growing at a CAGR of 12.42% ...
Ed Sheeran has celebrated changes to the national curriculum in England that mean more students will be able to study ...
New solution transforms fragile AI toolchains into tested, production-ready integrations to power AI workflows Prismatic MCP flow server MCP flow server for production-ready AI integrations. SIOUX ...
The reforms, unveiled by Education Secretary Bridget Phillipson, follow recommendations from Professor Becky Francis’s ...
How AI, robotics, and precision medicine are transforming cancer care—bridging hope, technology, and humanity in the ongoing ...
QIAGEN today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The ...
AZoLifeSciences on MSN
RNA Molecules Alter Genome Structure to Silence Critical Neuronal Genes During Stress
What if the brain's response to stress could be read not in fleeting neurotransmitter bursts, but in the quieting of genes ...
The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results